Diagnosing pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 in daily practice.

Autor:	van Beek DJ; Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Pieterman CRC; Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Wessels FJ; Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands., van de Ven AC; Department of Endocrinology, Radboud University Medical Center, Nijmegen, Netherlands., de Herder WW; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands., Dekkers OM; Departments of Endocrinology and Metabolism and Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands., Zandee WT; Department of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands., Drent ML; Department of Internal Medicine, Section of Endocrinology, Amsterdam University Medical Center (UMC) Location Vrije Universiteit (VU) University Medical Center, Amsterdam, Netherlands., Bisschop PH; Department of Endocrinology and Metabolism, Amsterdam University Medical Center (UMC) Location Academic Medical Center, Amsterdam, Netherlands., Havekes B; Department of Internal Medicine, Division of Endocrinology, Maastricht University Medical Center, Maastricht, Netherlands., Borel Rinkes IHM; Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Vriens MR; Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Valk GD; Department of Endocrine Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
Jazyk:	angličtina
Zdroj:	Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Oct 07; Vol. 13, pp. 926491. Date of Electronic Publication: 2022 Oct 07 (Print Publication: 2022).
DOI:	10.3389/fendo.2022.926491
Abstrakt:	Background: In multiple endocrine neoplasia type 1 (MEN1), pancreatic neuroendocrine tumors (PanNETs) have a high prevalence and represent the main cause of death. This study aimed to assess the diagnostic accuracy of the currently used conventional pancreatic imaging techniques and the added value of fine needle aspirations (FNAs). Methods: Patients who had at least one imaging study were included from the population-based MEN1 database of the DutchMEN Study Group from 1990 to 2017. Magnetic resonance imaging (MRI), computed tomography (CT), endoscopic ultrasonography (EUS), FNA, and surgical resection specimens were obtained. The first MRI, CT, or EUS was considered as the index test. For a comparison of the diagnostic accuracy of MRI versus CT, patients with their index test taken between 2010 and 2017 were included. The reference standard consisted of surgical histopathology or radiological follow-up. Results: A total of 413 patients (92.8% of the database) underwent 3,477 imaging studies. The number of imaging studies per patient increased, and a preference for MRI was observed in the last decade. Overall diagnostic accuracy was good with a positive (PPV) and negative predictive value (NPV) of 88.9% (95% confidence interval, 76.0-95.6) and 92.8% (89.4-95.1), respectively, for PanNET in the pancreatic head and 92.0% (85.3-96.0) and 85.3% (80.5-89.1), respectively, in the body/tail. For MRI, PPV and NPV for pancreatic head tumors were 100% (76.1-100) and 87.1% (76.3-93.6) and for CT, 60.0% (22.9-88.4) and 70.4% (51.3-84.3), respectively. For body/tail tumors, PPV and NPV were 91.3% (72.0-98.8) and 87.0% (75.3-93.9), respectively, for MRI and 100% (74.9-100) and 77.8% (54.3-91.5), respectively, for CT. Pathology confirmed a PanNET in 106 out of 110 (96.4%) resection specimens. FNA was performed on 34 lesions in 33 patients and was considered PanNET in 24 [all confirmed PanNET by histology (10) or follow-up (14)], normal/cyst/unrepresentative in 6 (all confirmed PanNET by follow-up), and adenocarcinoma in 4 (2 confirmed and 2 PanNET). Three patients, all older than 60 years, had a final diagnosis of pancreatic adenocarcinoma. Conclusion: As the accuracy for diagnosing MEN1-related PanNET of MRI was higher than that of CT, MRI should be the preferred (non-invasive) imaging modality for PanNET screening/surveillance. The high diagnostic accuracy of pancreatic imaging and the sporadic occurrence of pancreatic adenocarcinoma question the need for routine (EUS-guided) FNA. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 van Beek, Pieterman, Wessels, van de Ven, de Herder, Dekkers, Zandee, Drent, Bisschop, Havekes, Borel Rinkes, Vriens and Valk.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu